Merck & Co. Inc.

07/27/2021 | Press release | Distributed by Public on 07/27/2021 04:36

FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant[...]